bioRxiv · 10.64898/2026.03.22.713512
Mucin-binding protein shuttles enable delivery of brain-targeted therapeutics
Abstract
The blood-brain barrier (BBB) poses a major obstacle to the delivery of therapeutics into the central nervous system (CNS) due to its highly restrictive permeability. Here, we introduce glycan-targeted delivery vehicles, or GlycoShuttles, that traverse the BBB by harnessing the cerebrovascular glycocalyx, a carbohydrate-rich layer lining the BBB lumen. We discover that mucin-domain glycoproteins within this structure serve as novel entry portals for brain delivery and engineer mucin-binding protein shuttles that enable efficient transport of diverse molecular cargo across the BBB into multiple key brain cell types. This modular platform facilitates enhanced brain delivery of a variety of payloads, including antibodies and lysosomal proteins, and demonstrates therapeutic efficacy in mouse models of dementia. Our findings establish mucin-targeted GlycoShuttles as a versatile platform for noninvasive brain delivery of therapeutics, opening new avenues for the treatment of CNS diseases.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Shi, S. M., Tender, G. S., Xiong, J., Buff, J. K., Park, H. I., Mendiola, J. H., Wilson, E. N., Abu-Remaileh, M., Bertozzi, C. R., Wyss-Coray, T.. 2026-03-25. Mucin-binding protein shuttles enable delivery of brain-targeted therapeutics. https://doi.org/10.64898/2026.03.22.713512
Cite the original work for its findings. Save a collection to share your selection of sources.